Trial Profile
A Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 After a Single and Multiple Ascending Oral Doses in Healthy Subjects and Patients With Primary Mitochondrial Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs KL 1333 (Primary)
- Indications Mitochondrial disorders
- Focus Adverse reactions
- Sponsors Abliva
- 16 Mar 2021 According to an Abliva media release, the study was led by Prof. Gorman, and Dr. Pitceathly.
- 16 Mar 2021 According to an Abliva media release, the study data will be evaluated during the spring and early summer.
- 16 Mar 2021 Results published in the Abliva Media Release.